Drug Trial Radar · NCT02099110
Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)
Last checked: Nov 20, 2026Latest source record: Sep 12, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,233
Actual
Start
Apr 22, 2014
Primary completion
May 26, 2016
Study completion May 26, 2016
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- Pfizer
- First posted
- Mar 28, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study of co-administration of ertugliflozin (MK-8835/PF-04971729) and sitagliptin given together or alone along with metformin in participants with Type 2 diabetes mellitus (T2DM) and inadequate glycemic control on metformin monotherapy. The primary hypothesis of this study is that ertugliflozin 15 mg daily plus sitagliptin 100 mg daily provides greater hemoglobin A1C (A1C)-lowering compared with sitagliptin 100 mg daily alone.
Conditions
- Type 2 Diabetes Mellitus
Interventions
Matching Placebo to Ertugliflozin 5 mgDrug
Placebo to ertugliflozin 5 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
Matching Placebo to Ertugliflozin 10 mgDrug
Placebo to ertugliflozin 10 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
Matching Placebo to sitagliptin 100 mgDrug
Placebo to sitagliptin 100 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
Ertugliflozin 5 mgDrug
Ertugliflozin 5 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
Ertugliflozin 10 mgDrug
Ertugliflozin 10 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
Sitagliptin 100 mgDrug
Sitagliptin 100 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
Metformin >= 1500 mg/dayDrug
Metformin \>= 1500 mg/day, tablets, oral, for 52 weeks while receiving blinded investigational product during the double-blind treatment period
Insulin Glargine Rescue MedicationBiological
Open-label insulin glargine, subcutaneous injection, as required as a rescue medication; dose determined per the investigator's discretion
Glimepiride Rescue MedicationDrug
Open-label glimepiride tablets, oral, as required as a rescue medication, dose determined per the investigator's discretion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in A1C at Week 26: Excluding Rescue ApproachTime frame: Baseline and Week 26
- Percentage of Participants Who Experienced an Adverse Event (AE): Including Rescue ApproachTime frame: Up to 54 weeks
- Percentage of Participants Who Discontinued Study Treatment Due to an AE: Including Rescue ApproachTime frame: Up to 52 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.